207 related articles for article (PubMed ID: 34621020)
21. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A
Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589
[TBL] [Abstract][Full Text] [Related]
22. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A
Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460
[TBL] [Abstract][Full Text] [Related]
23. Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors.
Hsueh YS; Chang HH; Shan YS; Sun HS; Fletcher JA; Li CF; Chen LT
Oncogene; 2019 Sep; 38(38):6550-6565. PubMed ID: 31363162
[TBL] [Abstract][Full Text] [Related]
24. Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.
Edris B; Willingham SB; Weiskopf K; Volkmer AK; Volkmer JP; Mühlenberg T; Montgomery KD; Contreras-Trujillo H; Czechowicz A; Fletcher JA; West RB; Weissman IL; van de Rijn M
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3501-6. PubMed ID: 23382202
[TBL] [Abstract][Full Text] [Related]
25. Anti-KIT DNA Aptamer for Targeted Labeling of Gastrointestinal Stromal Tumor.
Banerjee S; Yoon H; Yebra M; Tang CM; Gilardi M; Shankara Narayanan JS; White RR; Sicklick JK; Ray P
Mol Cancer Ther; 2020 May; 19(5):1173-1182. PubMed ID: 32127469
[TBL] [Abstract][Full Text] [Related]
26. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.
Zeng C; Zhu L; Jia X; Pang Y; Li Z; Lu X; Xie F; Duan L; Wang Y
Gastric Cancer; 2020 Sep; 23(5):837-847. PubMed ID: 32291709
[TBL] [Abstract][Full Text] [Related]
27. Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib.
Li CF; Fang FM; Chen YY; Liu TT; Chan TC; Yu SC; Chen LT; Huang HY
Clin Cancer Res; 2017 Aug; 23(16):4908-4918. PubMed ID: 28442505
[No Abstract] [Full Text] [Related]
28. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
29. DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.
Simon S; Grabellus F; Ferrera L; Galietta L; Schwindenhammer B; Mühlenberg T; Taeger G; Eilers G; Treckmann J; Breitenbuecher F; Schuler M; Taguchi T; Fletcher JA; Bauer S
Cancer Res; 2013 Jun; 73(12):3661-70. PubMed ID: 23576565
[TBL] [Abstract][Full Text] [Related]
30. Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib.
Zeng X; Zhao F; Jia J; Ma X; Jiang Q; Zhang R; Li C; Wang T; Liu W; Hao Y; Tao K; Lou Z; Zhang P
Cancer Res; 2023 Nov; 83(21):3624-3635. PubMed ID: 37556508
[TBL] [Abstract][Full Text] [Related]
31. FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.
Li F; Huynh H; Li X; Ruddy DA; Wang Y; Ong R; Chow P; Qiu S; Tam A; Rakiec DP; Schlegel R; Monahan JE; Huang A
Cancer Discov; 2015 Apr; 5(4):438-51. PubMed ID: 25673643
[TBL] [Abstract][Full Text] [Related]
32. Ethyl-2-amino-pyrrole-3-carboxylates are active against imatinib-resistant gastrointestinal stromal tumors in vitro and in vivo.
Boichuk S; Galembikova A; Dunaev P; Micheeva E; Novikova M; Khromova N; Kopnin P
Anticancer Drugs; 2019 Jun; 30(5):475-484. PubMed ID: 30986804
[TBL] [Abstract][Full Text] [Related]
33. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
[TBL] [Abstract][Full Text] [Related]
34. Proteogenomics for the Study of Gastrointestinal Stromal Tumors.
Kondo T
Adv Exp Med Biol; 2016; 926():139-151. PubMed ID: 27686810
[TBL] [Abstract][Full Text] [Related]
35. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
[TBL] [Abstract][Full Text] [Related]
36. Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.
Kim TS; Cavnar MJ; Cohen NA; Sorenson EC; Greer JB; Seifert AM; Crawley MH; Green BL; Popow R; Pillarsetty N; Veach DR; Ku AT; Rossi F; Besmer P; Antonescu CR; Zeng S; Dematteo RP
Clin Cancer Res; 2014 May; 20(9):2350-62. PubMed ID: 24583793
[TBL] [Abstract][Full Text] [Related]
37. Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours.
Mu J; Sun P; Ma Z; Sun P
J Cell Mol Med; 2020 Feb; 24(4):2519-2530. PubMed ID: 31957165
[TBL] [Abstract][Full Text] [Related]
38. DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors.
Liu A; Zhang S; Wang M; Zhang L; Xu S; Nasimian A; Li S; Zhao S; Cao X; Tian J; Yu Y; Fan Z; Xiao K; Zhao H; Kazi JU; Ma L; Sun J
Mol Carcinog; 2024 Jan; 63(1):75-93. PubMed ID: 37737519
[TBL] [Abstract][Full Text] [Related]
39. SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib.
Li S; Zhao S; Liang N; Zhang S; Zhang L; Zhou L; Liu A; Cao X; Tian J; Yu Y; Fan Z; Xiao K; Wang M; Zhao H; Bai R; Sun J
Gastric Cancer; 2023 Sep; 26(5):677-690. PubMed ID: 37222910
[TBL] [Abstract][Full Text] [Related]
40. [Establishment and pathologic analysis of imatinib-resistant gastrointestinal stromal tumor xenografts].
Zheng S; Wang XJ; Jia J; Pan YL; Tao DY; Lu HS; Huang KE
Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):176-80. PubMed ID: 22800481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
